Notis McConarty Edward Has $2.53 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Notis McConarty Edward trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,136 shares of the medical instruments supplier’s stock after selling 376 shares during the quarter. Becton, Dickinson and Company comprises about 1.2% of Notis McConarty Edward’s portfolio, making the stock its 29th biggest position. Notis McConarty Edward’s holdings in Becton, Dickinson and Company were worth $2,526,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company during the 4th quarter worth approximately $25,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company during the fourth quarter worth $29,000. Picton Mahoney Asset Management increased its stake in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 54 shares in the last quarter. Hopwood Financial Services Inc. acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $39,000. Finally, Versant Capital Management Inc boosted its position in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 73 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 459 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the transaction, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Down 6.1 %

NYSE BDX opened at $208.03 on Friday. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $230.06 and a 200 day simple moving average of $231.33. Becton, Dickinson and Company has a 12 month low of $204.95 and a 12 month high of $251.99. The firm has a market capitalization of $59.73 billion, a P/E ratio of 34.56, a PEG ratio of 1.63 and a beta of 0.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.00%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 69.10%.

Wall Street Analyst Weigh In

A number of analysts recently commented on BDX shares. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Barclays increased their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.